These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 21480822)

  • 1. Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.
    Zhang Z; Krimmel J; Zhang Z; Hu Z; Seth P
    Hum Gene Ther; 2011 Sep; 22(9):1137-42. PubMed ID: 21480822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.
    Xu W; Zhang Z; Yang Y; Hu Z; Wang CH; Morgan M; Wu Y; Hutten R; Xiao X; Stock S; Guise T; Prabhakar BS; Brendler C; Seth P
    Mol Ther; 2014 Aug; 22(8):1504-1517. PubMed ID: 24791939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.
    Xu W; Yang Y; Hu Z; Head M; Mangold KA; Sullivan M; Wang E; Saha P; Gulukota K; Helseth DL; Guise T; Prabhkar BS; Kaul K; Schreiber H; Seth P
    Hum Gene Ther; 2020 Aug; 31(15-16):863-880. PubMed ID: 32394753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model.
    Hu Z; Zhang Z; Guise T; Seth P
    Hum Gene Ther; 2010 Nov; 21(11):1623-9. PubMed ID: 20712434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.
    Hu Z; Gerseny H; Zhang Z; Chen YJ; Berg A; Zhang Z; Stock S; Seth P
    Mol Ther; 2011 Sep; 19(9):1609-18. PubMed ID: 21712815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species D Adenoviruses as Oncolytic Viral Vectors.
    Bullard BL; Corder BN; Weaver EA
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33291224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.
    Zhang Z; Hu Z; Gupta J; Krimmel JD; Gerseny HM; Berg AF; Robbins JS; Du H; Prabhakar B; Seth P
    Cancer Gene Ther; 2012 Sep; 19(9):630-6. PubMed ID: 22744210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.
    Shashkova EV; May SM; Doronin K; Barry MA
    Mol Ther; 2009 Dec; 17(12):2121-30. PubMed ID: 19755961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model.
    Hu Z; Gupta J; Zhang Z; Gerseny H; Berg A; Chen YJ; Zhang Z; Du H; Brendler CB; Xiao X; Pienta KJ; Guise T; Lee C; Stern PH; Stock S; Seth P
    Hum Gene Ther; 2012 Aug; 23(8):871-82. PubMed ID: 22551458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
    Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
    Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K
    Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.
    Yang Y; Xu W; Neill T; Hu Z; Wang CH; Xiao X; Stock SR; Guise T; Yun CO; Brendler CB; Iozzo RV; Seth P
    Hum Gene Ther; 2015 Dec; 26(12):813-25. PubMed ID: 26467629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.
    Short JJ; Rivera AA; Wu H; Walter MR; Yamamoto M; Mathis JM; Curiel DT
    Mol Cancer Ther; 2010 Sep; 9(9):2536-44. PubMed ID: 20736345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
    Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
    Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel oncolytic adenovirus based on simian adenovirus serotype 24.
    Cheng T; Song Y; Zhang Y; Zhang C; Yin J; Chi Y; Zhou D
    Oncotarget; 2017 Apr; 8(16):26871-26885. PubMed ID: 28460470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma.
    Chen W; Wu Y; Liu W; Wang G; Wang X; Yang Y; Chen W; Tai Y; Lu M; Qian Q; Zhang Q; Chen G
    Cancer Lett; 2011 Aug; 307(1):93-103. PubMed ID: 21504839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.
    Callegari E; Elamin BK; D'Abundo L; Falzoni S; Donvito G; Moshiri F; Milazzo M; Altavilla G; Giacomelli L; Fornari F; Hemminki A; Di Virgilio F; Gramantieri L; Negrini M; Sabbioni S
    PLoS One; 2013; 8(9):e73964. PubMed ID: 24069256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.
    Wong HH; Jiang G; Gangeswaran R; Wang P; Wang J; Yuan M; Wang H; Bhakta V; Müller H; Lemoine NR; Wang Y
    Mol Ther; 2012 Feb; 20(2):306-16. PubMed ID: 22086234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
    He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.